ALBERT B DEISSEROTH
Medical Practice at Lamplighter Ln, Rockville, MD
License number
Florida 17824
Issued Date
Dec 31, 1973
Effective Date
Jan 1, 1901
Expiration Date
Dec 31, 1989
Category
Health Care
Type
Medical Doctor
Address
Address
1115 Lamplighter Ln, Rockville, MD 20854
Professional information
Dr. Albert B Deisseroth, Potomac MD - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
11609 Deborah Dr, Potomac 20854
Certifications:
Hematology, 1976, Internal Medicine, 1973, Medical Oncology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Rochester
Graduated: 1970
Beth Israel Deaconess Medical Center
National Institutes Of Health Clinical Center
Childrens Hospital
Harvard Medical School
University of Rochester
Graduated: 1970
Beth Israel Deaconess Medical Center
National Institutes Of Health Clinical Center
Childrens Hospital
Harvard Medical School
Composition Comprising An Adenoviral Expression Vector Comprising A Cd40L Fusion Protein For Generating Immune Responses
US Patent:
8236295, Aug 7, 2012
Filed:
Feb 2, 2012
Appl. No.:
13/364370
Inventors:
Albert B. Deisseroth - Potomac MD, US
Lixin Zhang - Houston TX, US
Lixin Zhang - Houston TX, US
Assignee:
VAXum, LLC - Manassas VA
International Classification:
A61K 48/00, C12N 15/00
US Classification:
424 932, 424 936, 4241991, 4353201
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
Methods Of Generating Immune Responses With Compositions Comprising An Adenoviral Expression Vector Comprising A Cd40L Fusion Protein
US Patent:
8540979, Sep 24, 2013
Filed:
Jul 16, 2012
Appl. No.:
13/549581
Inventors:
Albert B. Deisseroth - Potomac MD, US
Lixin Zhang - Houston TX, US
Lixin Zhang - Houston TX, US
Assignee:
VAXum, LLC - Manassas VA
International Classification:
A61K 48/00, C12N 15/00
US Classification:
424 932, 4241991, 4353201, 514 44 R
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
Pharmaceutical Compositions And Methods Of Blocking Bacillus Anthracis
US Patent:
2013014, Jun 13, 2013
Filed:
Feb 5, 2013
Appl. No.:
13/759224
Inventors:
Albert B. Deisseroth - Potomac MD, US
Assignee:
MICROVAX, LLC - Manassas VA
International Classification:
A61K 39/07
US Classification:
4241921, 4241991, 4242461
Abstract:
The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of in an individual. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of or fragment thereof attached via a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies and/or cytotoxic T cells which inhibit or block infection in an individual.
Mucin Antigen Vaccine
US Patent:
2014007, Mar 13, 2014
Filed:
Jul 23, 2013
Appl. No.:
13/948573
Inventors:
Albert Deisseroth - Potomac MD, US
Assignee:
MicroVAX, LLC. - Manassas VA
International Classification:
C12N 15/85
US Classification:
4353201
Abstract:
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.
Adenoviral Vector Vaccine
US Patent:
2014008, Mar 20, 2014
Filed:
Aug 23, 2013
Appl. No.:
13/974353
Inventors:
Albert B. Deisseroth - Potomac MD, US
Lixin Zhang - Houston TX, US
Lixin Zhang - Houston TX, US
Assignee:
VAXum, LLC - Manassas VA
International Classification:
C07K 14/705, C07K 14/005
US Classification:
4353201
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
Mucin Antigen Vaccine
US Patent:
8501707, Aug 6, 2013
Filed:
Oct 29, 2012
Appl. No.:
13/662616
Inventors:
Albert Deisseroth - Potomac MD, US
Assignee:
MicroVAX, LLC - Manassas VA
International Classification:
C07H 21/04, A61K 39/00, A61K 39/12
US Classification:
514 44R, 536 234, 4241921, 4241991
Abstract:
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.